Lampert Mark N
Director, 10% owner at MLTX; Director, 10% owner at CELL THERAPEUTICS INC; 10% owner at PTN, and 4 more
- Sold, on record
- $143M
- Dollars the filings state
- Form 4 sales
- 7
- Latest Mar 31, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 7
- Filed as an executive or holder
Companies
- MLTXMoonLake ImmunotherapeuticsDirector, 10% owner
- CELL THERAPEUTICS INCDirector, 10% owner
- PTNPALATIN TECHNOLOGIES INC10% owner
- ARQULE INC10% owner
- AVIGEN INC \DE10% owner
- NEUROBIOLOGICAL TECHNOLOGIES INC /CA/10% owner
- ADOLOR CORP10% owner
Sales by reason
0
Routine
3
Plan not stated
0
No plan
4
Unusual
Form 4 sales per year, every sale on record.
Sales by company
- CELL THERAPEUTICS INC8.5M shares
- NEUROBIOLOGICAL TECHNOLOGIES INC /CA/4.6M shares
- ARQULE INC3.8M shares
- MLTX3.8M shares
- ADOLOR CORP354,000 shares
- PTN305,966 shares
- AVIGEN INC \DE626 shares
Shares sold, every Form 4 sale on record.
Timeline
- Mar 31, 2026Unusual
Sold 78.3% of their holdings
$63M3.8M shares at $16.79
- Aug 9, 2022Unusual
Sold 99.8% of their holdings
$52M8.5M shares at $6.12
- Feb 19, 2014Plan not stated
Sold 9.1% of their holdings
$357k305,966 shares at $1.17
- Apr 1, 2010Unusual
Sold 43.8% of their holdings
$22.9M3.8M shares at $6.11
- Nov 18, 2009Plan not stated
Sold under 0.1% of their holdings
$939626 shares at $1.50
- Oct 21, 2009Unusual
NEUROBIOLOGICAL TECHNOLOGIES INC /CA/
Sold 93.3% of their holdings
$4.2M4.6M shares at $0.91
- Sep 22, 2009Plan not stated
Sold 7.9% of their holdings
$599k354,000 shares at $1.69
7 of 7
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | Jun 23, 2026 | OLMA | Director | AwardedStock Option (Right to buy) | 29,500 | 29,500 | SEC | ||
| Mar 31, 2026 | Apr 2, 2026 | MLTX | Director, 10% owner | Sold | 3.8M | $16.79 | $63M | 1M | SEC |
| Jun 15, 2023 | Jun 20, 2023 | KYMR | Director | AwardedStock Option (Right to Buy) | 12,000 | 12,000 | SEC | ||
| Aug 9, 2022 | Aug 11, 2022 | CELL THERAPEUTICS INC | Director, 10% owner | Sold | 8.5M | $6.12 | $52M | 6,148 | SEC |
| Aug 9, 2022 | Aug 11, 2022 | CELL THERAPEUTICS INC | Director, 10% owner | ConvertedSeries O Convertible Preferred Stock | 12,575 | 0 | SEC | ||
| Aug 9, 2022 | Aug 11, 2022 | CELL THERAPEUTICS INC | Director, 10% owner | Converted | 8.4M | 1.5M | SEC | ||
| Apr 26, 2021 | Apr 27, 2021 | Rain Oncology Inc. | Other | Awarded | 1.1M | $16.86 | $19.1M | 88,226 | SEC |
| Apr 23, 2021 | Apr 27, 2021 | Rain Oncology Inc. | Other | ConvertedSeries A Convertible Preferred Stock | 3.8M | 0 | SEC | ||
| Apr 23, 2021 | Apr 27, 2021 | Rain Oncology Inc. | Other | Converted | 3.8M | 286,691 | SEC | ||
| Mar 30, 2021 | Apr 1, 2021 | Merus N.V. | 10% owner | Bought | 300,000 | $19.75 | $5.9M | 462,015 | SEC |
| Mar 16, 2021 | Mar 18, 2021 | Merus N.V. | 10% owner | Bought | 250,000 | $23.00 | $5.8M | 427,377 | SEC |
| Dec 22, 2020 | Dec 28, 2020 | ELDN | Other | ConvertedSeries X Convertible Preferred | 23,213 | 6,758 | SEC | ||
| Dec 22, 2020 | Dec 28, 2020 | ELDN | Other | Converted | 1.3M | 113,152 | SEC | ||
| Aug 21, 2020 | Aug 25, 2020 | KYMR | Other | ConvertedSeries C Preferred Stock | 2.5M | 0 | SEC | ||
| Aug 21, 2020 | Aug 25, 2020 | KYMR | Other | Converted | 1.6M | 113,290 | SEC | ||
| Aug 21, 2020 | Aug 25, 2020 | KYMR | Other | Awarded | 978,693 | $20.00 | $19.6M | 181,081 | SEC |
| Aug 20, 2020 | Aug 25, 2020 | KYMR | Other | AwardedStock Option (Right to Buy) | 40,127 | 40,127 | SEC | ||
| Mar 4, 2020 | Mar 4, 2020 | CELL THERAPEUTICS INC | 10% owner | BoughtSeries X Convertible Preferred Stock | 1,921 | 12 | SEC | ||
| Mar 2, 2020 | Mar 4, 2020 | CELL THERAPEUTICS INC | 10% owner | Exercised or settledSubscription Rights (right to buy) | 2,252 | 104 | SEC | ||
| Dec 19, 2019 | Dec 20, 2019 | XOMA LTD /DE/ | 10% owner | Bought | 373,195 | $22.00 | $8.2M | 1.1M | SEC |
| Dec 18, 2019 | Dec 20, 2019 | XOMA LTD /DE/ | 10% owner | Exercised or settledSubscription Rights (right to buy) | 472,268 | 0 | SEC | ||
| Dec 18, 2019 | Dec 20, 2019 | XOMA LTD /DE/ | 10% owner | Exercised options | 472,268 | $22.00 | $10.4M | 159,537 | SEC |
| Nov 20, 2019 | Nov 22, 2019 | Calithera Biosciences, Inc. | 10% owner | Bought | 191,954 | $3.91 | $751k | 672,682 | SEC |
| Nov 14, 2019 | Nov 18, 2019 | Calithera Biosciences, Inc. | 10% owner | Bought | 128,488 | $3.37 | $433k | 658,531 | SEC |
| Oct 31, 2019 | Oct 31, 2019 | FIVE PRIME THERAPEUTICS INC | 10% owner | Bought | 29,314 | $3.88 | $114k | 348,827 | SEC |
| Mar 27, 2018 | Mar 29, 2018 | XENE | 10% owner | OtherSeries 1 Preferred Shares | 2.4M | 238,000 | SEC | ||
| Mar 27, 2018 | Mar 29, 2018 | XENE | 10% owner | Other | 2.4M | 59,464 | SEC | ||
| Feb 9, 2018 | Feb 12, 2018 | CELL THERAPEUTICS INC | 10% owner | Bought | 6.3M | $3.00 | $19M | 1.3M | SEC |
| Feb 9, 2018 | Feb 12, 2018 | CELL THERAPEUTICS INC | 10% owner | Returned to the companySeries N Preferred Stock | 575 | 0 | SEC | ||
| Feb 9, 2018 | Feb 12, 2018 | CELL THERAPEUTICS INC | 10% owner | Returned to the company | 8M | 596,357 | SEC | ||
| Feb 9, 2018 | Feb 12, 2018 | CELL THERAPEUTICS INC | 10% owner | AwardedSeries O Preferred Stock | 12,575 | 2,280 | SEC | ||
| Jun 22, 2017 | Jun 23, 2017 | XENE | 10% owner | Bought | 20,411 | $4.00 | $82k | 288,968 | SEC |
| May 31, 2017 | Jun 1, 2017 | ALPINE IMMUNE SCIENCES, INC. | 10% owner | Bought | 47,000 | $2.27 | $107k | 192,503 | SEC |
| Jul 1, 2014 | Jul 10, 2014 | ARRAY BIOPHARMA INC | Other | Other | 494,092 | $4.56 | $2.3M | 7.1M | SEC |
| Jul 1, 2014 | Jul 3, 2014 | CAPS | 10% owner | Other | 616,563 | $0.30 | $185k | 4M | SEC |
| Feb 19, 2014 | Feb 19, 2014 | PTN | 10% owner | Sold | 305,966 | $1.17 | $357k | 3.1M | SEC |
| Aug 8, 2013 | Aug 12, 2013 | Oncothyreon Inc. | 10% owner | Bought | 258,361 | $1.65 | $426k | 2.6M | SEC |
| Jun 7, 2013 | Jun 11, 2013 | RIGL | 10% owner | Bought | 32,700 | $3.47 | $113k | 799,615 | SEC |
| Nov 16, 2012 | Nov 19, 2012 | GYRE | 10% owner | Bought | 1.3M | $4.06 | $5.2M | 1.5M | SEC |
| Nov 6, 2012 | Nov 8, 2012 | ChemoCentryx, Inc. | 10% owner | Bought | 40,000 | $12.00 | $480k | 3.8M | SEC |
| Nov 2, 2012 | Nov 2, 2012 | GYRE | 10% owner | Bought | 139,700 | $4.05 | $566k | 1M | SEC |
| Oct 31, 2012 | Nov 2, 2012 | LGND | 10% owner | Bought | 16,591 | $15.19 | $252k | 741,627 | SEC |
| Oct 26, 2011 | Oct 28, 2011 | LGND | 10% owner | Bought | 6,020 | $13.91 | $84k | 1.7M | SEC |
| Oct 13, 2011 | Oct 14, 2011 | LGND | 10% owner | Bought | 75,353 | $13.65 | $1M | 1.7M | SEC |
| Sep 7, 2011 | Sep 9, 2011 | ICAGEN INC | 10% owner | Bought | 126,700 | $6.00 | $760k | 625,400 | SEC |
| Aug 22, 2011 | Aug 22, 2011 | CAPS | 10% owner | Bought | 78,900 | $0.26 | $21k | 4.4M | SEC |
| Jul 20, 2011 | Jul 22, 2011 | CAPS | 10% owner | Bought | 252,600 | $0.25 | $63k | 3.7M | SEC |
| Jul 18, 2011 | Jul 18, 2011 | CAPS | 10% owner | Bought | 358,600 | $0.25 | $90k | 3.5M | SEC |
| May 9, 2011 | May 10, 2011 | Celera CORP | 10% owner | Bought | 1.6M | $8.05 | $12.7M | 15.8M | SEC |
| Apr 6, 2011 | Apr 7, 2011 | Celera CORP | 10% owner | Bought | 182,000 | $8.21 | $1.5M | 9.5M | SEC |
Page 1
Sales and notices (7)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | Apr 2, 2026 | MLTX | Director, 10% owner | Form 4 sale | 3.8M | $63M | 78.3% | Unusual | SEC |
| Aug 9, 2022 | Aug 11, 2022 | CELL THERAPEUTICS INC | Director, 10% owner | Form 4 sale | 8.5M | $52M | 99.8% | Unusual | SEC |
| Feb 19, 2014 | Feb 19, 2014 | PTN | 10% owner | Form 4 sale | 305,966 | $357k | 9.1% | Plan not stated | SEC |
| Apr 1, 2010 | Apr 2, 2010 | ARQULE INC | 10% owner | Form 4 sale | 3.8M | $22.9M | 43.8% | Unusual | SEC |
| Nov 18, 2009 | Nov 20, 2009 | AVIGEN INC \DE | 10% owner | Form 4 sale | 626 | $939 | 0.0% | Plan not stated | SEC |
| Oct 21, 2009 | Oct 23, 2009 | NEUROBIOLOGICAL TECHNOLOGIES INC /CA/ | 10% owner | Form 4 sale | 4.6M | $4.2M | 93.3% | Unusual | SEC |
| Sep 22, 2009 | Sep 24, 2009 | ADOLOR CORP | 10% owner | Form 4 sale | 354,000 | $599k | 7.9% | Plan not stated | SEC |